Featured Research

from universities, journals, and other organizations

VEGF Trap Shows Activity In Patients With Advanced Ovarian Cancer

Date:
June 4, 2007
Source:
Memorial Sloan-Kettering Cancer Center
Summary:
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents. The findings may indicate a role for this targeted therapy in women with ovarian cancer who have exhausted all other options.

Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents. The findings, which are being presented today at the American Society of Clinical Oncology's annual meeting, may indicate a role for this targeted therapy in women with ovarian cancer who have exhausted all other options.

To date, the trial has enrolled 162 patients with advanced ovarian cancer at 44 centers in twelve countries in Europe, Canada, and the United States. Favorable results were reported for 85 percent of participants after one month: 8 percent showed tumor shrinkage and 77 percent had stable disease. After fourteen weeks, 41 percent of patients continued to have stable disease.

"The interim analysis of the Phase II data was very promising," said Dr. William P. Tew, an oncologist at Memorial Sloan-Kettering Cancer Center and the study's lead author. "As a result, we are continuing to recruit patients to complete the study."

In this trial, VEGF Trap is administered intravenously as a single agent in one of two dose levels. It works by blocking the development of new blood vessels to the tumor (angiogenesis) which stops tumor growth and the spread of cancer to other parts of the body (metastasis). It can also result in tumor shrinkage. VEGF Trap is generally well-tolerated although both mild and severe side effects were reported. These included but were not limited to headache, fatigue, nausea, mild and severe hypertension, hoarseness, mild and severe protein in the urine, renal dysfunction, and a low incidence of bowel perforation (one percent).

"Ovarian cancer may be unusual among solid tumors because vascular-targeting agents like VEGF Trap appear to have significant single-agent activity in advanced ovarian cancer," said Dr. David R. Spriggs, Head of Solid Tumor Oncology at Memorial Sloan-Kettering and the study's senior author. "In most solid tumors, the efficacy of VEGF targeting is likely to be further enhanced by combining it with classic chemotherapy agents."

Epithelial ovarian cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. About 85 percent to 90 percent of all ovarian cancers are this type. The American Cancer Society estimates 22,430 women in the United States will be diagnosed with ovarian cancer in 2007 and 15,280 will die.

Nicoletta Colombo MD, Instituto Europeo di Oncologia; Isabella R. Coquard MD, Centre Leon Berard; Amit Oza MD, Princess Margaret Hospital; Jose Maria del Campo MD, Hospital de la Vall d'Hebron; and Giovanni Scambia MD, Universita Cattolica del Sacro Coure participated in this study. It was funded, in part, by grants from sanofi-aventis and Regeneron.


Story Source:

The above story is based on materials provided by Memorial Sloan-Kettering Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Memorial Sloan-Kettering Cancer Center. "VEGF Trap Shows Activity In Patients With Advanced Ovarian Cancer." ScienceDaily. ScienceDaily, 4 June 2007. <www.sciencedaily.com/releases/2007/06/070603215427.htm>.
Memorial Sloan-Kettering Cancer Center. (2007, June 4). VEGF Trap Shows Activity In Patients With Advanced Ovarian Cancer. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2007/06/070603215427.htm
Memorial Sloan-Kettering Cancer Center. "VEGF Trap Shows Activity In Patients With Advanced Ovarian Cancer." ScienceDaily. www.sciencedaily.com/releases/2007/06/070603215427.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins